Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Masahiro Takada"'
Autor:
Kaori Togashi, Akira Yamauchi, Hironori Kato, Nobuhiko Shinkura, Kenichi Yoshida, Kosuke Kawaguchi, Takahiro Yamada, Ryuji Okamura, Masahiro Sugimoto, Eiji Suzuki, Hironori Haga, Masae Torii, Hirofumi Suwa, Norimichi Kan, Sachiko Takahara, Yoshiaki Matsumoto, Masahiro Kawashima, Tsuyoshi Tachibana, Masakazu Toi, Yukiko Inagaki-Kawata, Hiroshi Yoshibayashi, Takashi Inamoto, Masako Kataoka, Shingo Sakata, Nobuko Kawaguchi-Sakita, Fumiaki Yotsumoto, Kazuhiko Yamagami, Yuki Kataoka, Mitsuru Tanaka, Shinji Kosugi, Masahiro Takada, Seishi Ogawa, Shigeru Tsuyuki, Tomomi Nishimura, Susumu Mashima, Noriko Senda, Yoshio Moriguchi
Publikováno v:
Cancer Science
Predicting pathogenic germline variants (PGVs) in breast cancer patients is important for selecting optimal therapeutics and implementing risk reduction strategies. However, PGV risk factors and the performance of prediction methods in the Japanese p
Publikováno v:
Annals of Breast Surgery. 7:7-7
Autor:
Hiroyasu Yamashiro, Tetsuya Taguchi, Nobuko Ogura, Tomoharu Sugie, Masakazu Toi, Ichiro Nakayama, Hiroshi Ishiguro, Shigeru Tsuyuki, Yuri Fujimoto, Tatsuji Kato, Sachiko Takahara, Hiroshi Yoshibayashi, Masahiro Takada, Tatsuo Kagimura, Yoshio Moriguchi, Kazuhiko Yamagami, Rie Yasuoka, Takeshi Kotake, Hirofumi Suwa, Yuichiro Kikawa, Toshitaka Okuno
Publikováno v:
Cancer Research. 81:PS13-31
BackgroundEribulin (E) is a chemotherapeutic drug that prolongs overall survival (OS) of patients with HER2-negative advanced or metastatic breast cancer (AMBC), mainly in multi-line chemotherapy (ChT) or later. However, the effectiveness and optimal
Autor:
Tomoharu Sugie, Yasuo Ohashi, Takanori Ishida, Hironori Haga, Akira Shimizu, Masahiro Takada, Nobuaki Sato, Shigehira Saji, Hiroshi Ishiguro, Kenjiro Aogi, Hiroji Iwata, Takayuki Kinoshita, Masahiro Kitada, Toshiaki Saeki, Yuichiro Kai, Yasuyuki Sato, Kenjiro Jimbo, Norikazu Masuda, Shigeru Imoto, Yoshinori Ito, Takafumi Ikeda, Hirofumi Mukai, Masakazu Toi, Takayuki Ueno, Shinji Ohno
Publikováno v:
The Lancet Oncology. 22:74-84
Oral fluoropyrimidines, such as S-1, have been shown to have a role in controlling disease progression in metastatic breast cancer. We examined adjuvant treatment with S-1 in patients with oestrogen receptor (ER)-positive and HER2-negative primary br
Autor:
Hiroji Iwata, Nami Yamashita, Fimikata Hara, Tatsuya Toyama, Rikiya Nakamura, Junji Tsurutani, Yasuaki Sagara, Toshiro Mizuno, Masaya Hattori, Shigenori Nagai, Yoichi Naito, Naoto Kondo, Hitoshi Arioka, Naoki Hayashi, Yuichiro Kikawa, Minoru Miyashita, Tatsunori Shimoi, Mikiya Ishihara, Toshimi Takano, Kei Koizumi, Masato Takahashi, Masahiro Takada, Tetsuhiro Yoshinami, Shigehira Saji, Takashi Yamanaka
Publikováno v:
Breast Cancer (Tokyo, Japan)
Purpose We present the English version of The Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition. Methods The JBCS formed a task force to update the JBCS Clinical Practice Guidelin
Autor:
Takashi Inamoto, Fumiaki Yotsumoto, Masahiro Kawashima, Masae Torii, Hiroshi Yoshibayashi, Masakazu Toi, Akira Yamauchi, Kenichi Yoshida, Nobuko Kawaguchi-Sakita, Mitsuru Tanaka, Shingo Sakata, Masahiro Sugimoto, Hirofumi Suwa, Nobuhiko Shinkura, Shigeru Tsuyuki, Yukiko Inagaki-Kawata, Yuki Kataoka, Yoshiaki Matsumoto, Tomomi Nishimura, Norimichi Kan, K Yamagami, Ryuji Okamura, Susumu Mashima, Fumiaki Sato, Hironori Kato, Yoshio Moriguchi, Noriko Senda, Tsuyoshi Tachibana, Masahiro Takada, Seishi Ogawa, Eiji Suzuki
Publikováno v:
Cancer Research. 80:P2-10
Background: Breast cancer risk models are used to predict the risk of carrying a variant, for one of the most common breast cancer susceptibility genes such as BRCA1 and BRCA2, and the lifetime risk of developing breast cancer. The prediction of harb
Autor:
Hiroshi Yoshibayashi, Kosuke Kawaguchi, Atsushi Yonezawa, Satoshi Morita, Hiroyasu Yamashiro, Reitaro Tokumasu, Hiroshi Ishiguro, Hirofumi Suwa, Tatsuki R. Kataoka, Takeshi Kotake, Maya Honda, Rikiya Yamashita, Laxmi Parida, Takahiko Koyama, Masahiro Takada, Michio Yoshimura, Masakazu Toi, Ryuji Uozumi, Masako Kataoka, Hironori Kato, Yuki Himoto, Natsuko Onishi, Wakako Tsuji
Publikováno v:
Cancer Research. 80:P3-09
BACKGROUND: In metastatic breast cancer, Overall Response Rate (ORR) for checkpoint inhibitor monotherapy has been limited. Since Radiation Therapy (RT) stimulates anti-cancer immune responses, we evaluated safety and efficacy of a combinatorial ther
Autor:
Toshiaki Saeki, Hironori Haga, Takafumi Ikeda, Hiroshi Ishiguro, Norikazu Masuda, Takanori Ishida, Yuichiro Kai, Takayuki Kinoshita, Nobuaki Sato, Masakazu Toi, Masahiro Takada, Yoshinori Ito, Hiroji Iwata, Shinji Ohno, Tomoharu Sugie, Yasuyuki Sato, Kenjiro Jimbo, Akira Shimizu, Shigehira Saji, Takayuki Ueno, Yasuo Ohashi, Kenjiro Aogi, Masahiro Kitada, Hirofumi Mukai, Shigeru Imoto
Publikováno v:
Cancer Research. 80:GS1-09
BACKGROUND: Although long-term prognostic outcomes of primary breast cancer (PBC) patients have been improved remarkably in recent years, the disease recurrence remains a serious problem. We have previously investigated a role for oral fluoropyrimidi
Autor:
Masakazu Toi, Hiroji Iwata, Tohru Ohtake, Naruto Taira, Masahiro Kashiwaba, Rikiya Nakamura, Tomomi Fujisawa, Yuichiro Kikawa, Masahiro Takada, Shinji Ohno, Yutaka Yamamoto, Satoshi Morita, Shigehira Saji, Yoshie Hasegawa, Tatsuya Toyama, Norikazu Masuda, Takanori Ishida, Masahiro Kitada, Uhi Toh, Toshimi Takano
Publikováno v:
Cancer Research. 80:P2-15
Background: The standard chemotherapy treatment strategy for patients with advanced/metastatic breast cancer (ABC) is the continuation of the same drug until tumor progression. However, despite continued antitumor effects, continuation of a drug ofte
Autor:
Satoshi Morita, Natsuko Onishi, Hiroshi Ishiguro, Michio Yoshimura, Takahiko Koyama, Hiroshi Yoshibayashi, Maya Honda, Hirofumi Suwa, Atsushi Yonezawa, Masahiro Takada, Kosuke Kawaguchi, Takeshi Kotake, Tatsuki R. Kataoka, Wakako Tsuji, Yuki Himoto, Rikiya Yamashita, Laxmi Parida, Masako Kataoka, Hironori Kato, Hiroyasu Yamashiro, Reitaro Tokumasu, Masakazu Toi, Ryuji Uozumi
Publikováno v:
Cancer Research. 80:P4-10
BACKGROUND: Advances in imuuno-oncology (IO), i.e., a programmed cell death protein 1 (PD-1) inhibitors are revolutionizing cancer treatment by offering hope for a cure. However, the benefit of IO agents in metastatic breast cancer (MBC) is still lim